Big Pharma Incubators May Provide Attractive Option to University Start-Ups Seeking Funds | GenomeWeb
University-spawned biotechnology startups seeking an infusion of cash to bridge the so-called investment “valley of death” now have another option to turn to in lieu of family, friends, angels, and venture capitalists: big pharma incubators.
Pfizer and Biogen-Idec have each established in-house incubators to nurture the development of university-based startup companies with the hope of garnering a return on their investment in the form of new tools to aid drug discovery and development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.